PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAlfacalcidol
Alfacalcidol
Alfacalcidol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
aranespBiologic Licensing Application2024-05-21
pulmozymeBiologic Licensing Application2024-11-13
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A11: Vitamins
A11C: Vitamin a and d, incl. combinations of the two
A11CC: Vitamin d and analogues
A11CC03: Alfacalcidol
M: Musculo-skeletal system drugs
M05: Drugs for treatment of bone diseases
M05B: Drugs affecting bone structure and mineralization
M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
M05BB06: Alendronic acid and alfacalcidol, sequential
HCPCS
No data
Clinical
Clinical Trials
1123 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic hyperplasiaD011470EFO_0000284N4011316
HyperplasiaD006965EFO_000053611316
Prostatic neoplasmsD011471C61213
HypogonadismD007006E23.011
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80112
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PsoriasisD011565EFO_0000676L4011
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.911
Drug interactionsD00434711
Bacterial infectionsD001424A4911
AlopeciaD000505L6411
Depressive disorderD003866EFO_1002014F32.A11
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlfacalcidol
INNalfacalcidol
Description
Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a member of D3 vitamins, a seco-cholestane, a hydroxycalciol and a diol. It is functionally related to a calciol.
Classification
Small molecule
Drug classvitamin D analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
Identifiers
PDB
CAS-ID41294-56-8
RxCUI
ChEMBL IDCHEMBL1601669
ChEBI ID31186
PubChem CID5282181
DrugBankDB01436
UNII IDURQ2517572 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,600 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aranesp
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,235 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use